Stock image of a young woman that is stressed out. Stress hormones, as a result of overeating and obesity, may increase our ...

Fasting at night prevents impairments in glucose tolerance among simulated night-shift work, according to a study pu ...

They explored three different cohorts: intensive-insulin treated, basal-insulin treated, and non-insulin treated, then evaluated their use of CGM both before and after initiating GLP-1 medications.

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

About embecta embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people ... Embecta Corporation Registered Shs When Issued NewsMORE Related ...

During the reported quarter, Insulet received FDA clearance for Omnipod 5, making it the first and only automated insulin ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Insulet stock soared out of a buy zone Friday after the insulin pump-maker "continued the beat-and-raise cadence it has seen in 2024." ...

Axon Enterprise ( AXON) was the best-performing stock in the S&P 500, with shares hitting an all-time high after the TASER ...

At about $69 per share, DexCom's stock isn't that far off its 52-week low of $62.34 ... for diabetics who aren't using insulin. And DexCom is building a network effect since its CGM systems are ...